Personalis Reports Q2 2025 Revenue of $17.2M, Net Loss $20.1M; Clinical Test Volume Up 59% Sequentially

Personalis, Inc.

2025-Q2 EPS reported -$0.41 vs consensus -$0.25 ▼ miss (-64.9%)

Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.
Revenue decreased 24% to $17.2M from $22.6M in Q2 2024, partly due to $5.6M decline from Natera.
Net loss was $20.1M ($0.23 per share) versus $12.8M ($0.24 per share) in Q2 2024.
Expanded Tempus AI collaboration to include colorectal cancer for exclusive commercialization.
Lowered full-year 2025 revenue guidance to $70-80M from $80-90M, citing biopharma headwinds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.